Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.
Sharp, a provider of commercial pharmaceutical packaging and clinical trial supply services, has acquired Berkshire Sterile Manufacturing (BSM), a fill-finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectable products.
The acquisition enables Sharp to now provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry; the company’s existing clinical supply, packaging, and distribution solutions are expected to complement BSM’s sterile manufacturing knowledge.
“The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies,” says Kevin Orfan, Sharp’s president and CEO. “With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise.”
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
485 Route 1 South,
Building F, Suite 210
Iselin, NJ 08830